Lv1
80 积分 2025-04-20 加入
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
23天前
已完结
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
23天前
已完结
TAS-102 for metastatic refractory colorectal cancer
23天前
已完结
Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing Thymidine Phosphorylase
1个月前
已完结
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
1个月前
已完结
Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance
1个月前
已完结
Ferroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targets
1个月前
已完结
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial
1个月前
已完结
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer
1个月前
已完结
Systemic treatment for metastatic colorectal cancer
1个月前
已完结
皖公网安备34019202002308
